Choice of Maintenance Medication for Schizophrenia

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 16, 2003, Pages 24-33

  Davis, John M ^a   Chen, Nancy ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SCREENING; DYSPHORIA; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INJECTION; LONG TERM CARE; MAINTENANCE THERAPY; META ANALYSIS; MOTOR DYSFUNCTION; OUTCOMES RESEARCH; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RATING SCALE; RELAPSE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; HUMANS; INJECTIONS, INTRAMUSCULAR; LONG-TERM CARE; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 0346753735     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (81)

1. Adams SG Jr, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993;181:558-560
2. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183
3. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Md: Williams and Wilkins; 1969
4. Agence National Pour le Development de L Evaluation Medicale. Strategies therapeutiques a long terme dans les psychoses schizophreniques. Text du consensus. Paris, France: Agence Nationale pour le Development de L Evaluation Medicale; 1994
5. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(4 suppl):1-63
6. The Canadian Psychiatric Association. Canadian Clinical Practice Guidelines for the Treatment of Schizophrenia. Can J Psychiatry 1998;43(suppl 2):25-40
7. Davis JM, Janicak PG. Risperidone: a new, novel (and better?) antipsychotic. Psychiatr Ann 1992;26:78-87
8. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757-771
9. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28:43-61
10. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546
11. Geddes J, Freemantle N, Harrison P, et al. The National Schizophrenia Guideline Development Group: atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
12. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
13. Davis JM, Chen N, Glick ID. Web supplement: a meta-analysis of the efficacy of second-generation antipsychotics. Available at: http:// www.psych.uic.edu/faculty/meta_analysis.pdf. Accessed June 23, 2003
14. Høyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402
15. Min SK, Rhee CS, Kim CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yansei Med J 1993;34:179-190
16. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. The Risperidone Study Group. Br J Psychiatry 1995; 166:712-726; discussion 727-733
17. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-258
18. Sikich L, Hamer R, Malekpour AH, et al. Double-blind trial comparing risperidone, olanzapine and haloperidol in the treatment of psychotic children and adolescents. Presented at the 40th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii
19. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159: 255-262
20. Zhang XY, Zhou DF, Cao LY, et al. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol 2001;16: 325-330
21. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38-44
22. Borison RL, Pathajira AP, Diamond BL, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218
23. Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol 2000;20:295-304
24. Cavallaro R, Mistretta P, Cocchi F, et al. Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. Hum Psychopharmacol Clin Exp 2001;16:439-448
25. Cešková E, Švestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121-124
26. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients [see comments] [published correction appears in J Clin Psychopharmacol 1993;13:149]. J Clin Psychopharmacol 1993;13:25-40
27. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients [see comments] [published correction appears in J Clin Psychopharmacol 1993;13:149]. J Clin Psychopharmacol 1993;13:25-40
28. Claus A, Bollen J, Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative trial. Acta Psychiatr Scand 1992;85:295-305
29. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
30. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25:721-729
31. Heck AH, Haffmans PM, de Groot IW, et al. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr Res 2000;46:97-105
32. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
33. Wirshing DA, Marshall BD, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374-1379
34. Lacro JP, Vanderswag H, Polichar D, et al. A randomized, double-blind comparison of risperidone vs haloperidol in older patients with schizophrenia or schizoaffective disorder. Presented at the 41st annual meeting of the New Clinical Drug Evaluation Unit; May 28-31, 2001; Phoenix, Ariz
35. Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995;91:271-277
36. Mahmoud RA, Engelhart LH. Risperidone versus conventional antipsychotics in usual care: a prospective randomised effectiveness trial of outcomes for patients with schizophrenia and schizoaffective disorder. Risperidone Outcome Study of Effectiveness (ROSE) Group and Janssen Research Foundation. Paper presented at the 11th CINP Congress; July 12-16, 1998; Glasgow, Scotland.
37. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
38. Bernardo M, Parellada E, Lomena F, et al. Double-blind olanzapine vs haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [123I]IBZM SPECT study. Psychiatry Res 2001; 107:87-97
39. Dittman RW, Geuppert MS, Diehl P, et al. Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Presented at the 8th International Congress on Schizophrenia Research; April 28-May 2, 2001; Whistler, Canada
40. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci 2001;55:403-414
41. Meehan KM, David SR, Taylor CC, et al. Change in positive symptoms with olanzapine in comparison with other antipsychotic agents. Presented at the 12th Congress of the European College of Neuropsychopharmacology; Sept 21-25, 1999; London, United Kingdom
42. Jakovljevic M, Dossenbach MR, Friedel P, et al, and the Olanzapine HGCH Study Group. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia. Psychiatria Danubina 1999;11:3-11
43. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
44. Beasley CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137
45. Tollefson GD, Beasley CMJ, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
46. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders [see comments]. J Clin Psychopharmacol 1997;17:407-418
47. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia. The Cochrane Library. Issue 2 ed. Oxford, England: Update Software; 2002
48. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920
49. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-813
50. Arato M, O'Connor R, Meltzer HY, for the ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-215
51. Hirsch SR, Kissling W, Bäuml J, et al. 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-523
52. Keck PE Jr, Reeves KR, Harrigan EP, for the Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001;21:27-35
53. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155: 128-134
54. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-18. Correction 2001;62:209
55. NDA 20-919: Zeldox (ziprasidone mesylate IM, Pfizer). Pfizer Global Research & Development. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2.htm. Accessed Jan 2, 2002
56. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136
57. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-399
58. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
59. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
60. Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (IC1 204, 636, "Seroquel") and haloperidol in schizophrenia. Psychol Med 2000;30:95-105
61. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ("Seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15:121-131
62. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
63. Csernansky JG, Mahmoud R, Brenner R, for the Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346: 16-22
64. Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry 2002;63(suppl 9):12-17
65. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173-188
66. Davis JM. Overview. Maintenance therapy in psychiatry, 1: schizophrenia. Am J Psychiatry 1975;132:1237-1245
67. Meltzer HY. Neuroleptic withdrawal in schizophrenic patients: an idea whose time has come. Arch Gen Psychiatry 1995;52:200-202
68. Davis JM, Metalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;45:751-773
69. Hogarty GE, Ulrich RF. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry 1977;34: 297-301
70. Hogarty GE, Ulrich RF, Mussare F, et al. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976;37:494-500
71. Greden JF, Tandon R. Long-term treatment for lifetime disease. Arch Gen Psychiatry 1995;52:197-200
72. Smith RC. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Arch Gen Psychiatry 1994;51: 427-429
73. Bollini P, Pampallona S, Orza MJ, et al. Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials. Psychol Med 1994;24:307-316
74. Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. Am J Psychiatry 1966;123:221-226
75. Branchey MH, Branchey LB, Richardson MA. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry 1981;138:608-612
76. Crow TJ, MacMillan JF, Johnson AL, et al. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-127
77. Levine J, Schooler NR, Severe J, et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Adv Biochem Psychopharmacol 1980; 24:483-493
78. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:189-192
79. Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54:49-55
80. Davis JM, Andriukaitis S. The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 1986; 6(1 suppl):2S-10S
81. Wyatt RJ. Risks of withdrawing antipsychotic medications. Arch Gen Psychiatry 1995;52:205-208